On March 1, 2022, Shanghai Longyao Biotechnology Co., Ltd. (Longyao Bio) LY007 project Phase I clinical officially enrolled the first subject in Ruijin Hospital Affiliated to Shanghai Jiaotong University (Ruijin Hospital). This project aims to evaluate the tolerability, safety and efficacy of LY007 cell injection in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma, and is a single-arm, open-label, multicenter Phase I Clinical Trials.
On January 21, 2021, Longyao Bio received the approval notice from the State Drug Administration for the approval of the clinical trial of the cell injection named LY007, and on January 25, 2022, and January 27, respectively, in Ruijin Hospital The kick-off meeting was successfully held with Jiangsu Provincial People's Hospital. The project was co-chaired by Vice President Zhao Weili of Ruijin Hospital and Director Li Jianyong of the Department of Hematology of Jiangsu Provincial People's Hospital.
About Products
LY007 cell injection is a CD20-targeting chimeric antigen receptor (CAR) autologous T cell injection that is genetically modified using lentiviral vector. Stimulates the signaling receptor OX40. Experiments have shown that this structure can reduce T cell exhaustion, enhance the proliferation and killing ability of CAR-T cells, and make it release more effectors, thereby improving CAR-T in terms of safety and efficacy. performance.
About Longyao Bio
Founded in 2013, Longyao Bio is located in Jing'an District, Shanghai. It is an independent innovation enterprise dedicated to the research and development of tumor immune cell drugs. The controlling shareholder is China Biotechnology Services Holdings Limited (8037.HK), a Hong Kong-listed company. Bio has the first and only CD20-targeted CAR-T product approved for clinical registration in China, and other products cover hematological tumors, solid tumors and other fields.